HER2-positive breast cancer accounts for approximately 15–20% of all breast cancer cases (10, 11), and is marked by HER2 overexpression, aggressive tumor behavior, shorter disease-free survival (DFS), and poorer prognosis (12–14). This evidence concerns the gene ERBB2 and breast cancer.